<DOC>
	<DOCNO>NCT00415038</DOCNO>
	<brief_summary>The purpose study verify efficacy Rostafuroxin treatment essential hypertension determine best effective dose administer general hypertensive population subset population genetic pattern could involve etiology essential hypertension .</brief_summary>
	<brief_title>Efficacy Rostafuroxin Treatment Essential Hypertension</brief_title>
	<detailed_description>Elevated arterial pressure probably important public health problem . 30 % world adult population affect hypertension industrialised country . Development pharmacogenomic approach therapy primary hypertension give new opportunity treatment hypertension . This approach consist identification genetic-molecular mechanism responsible hypertension give subset patient , development drug able interfere mechanism , thus lead selective therapeutic intervention enhance efficacy reduce side effect .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Patients grade 1 2 essential hypertension Less 3 risk factor ( age &gt; 55 male , smoking , dyslipidemia , family history CV disease occur 55 year men 65 woman Naive patient currently monotherapy one combination tablet SBP 140 169 mmHg Atrial fibrillation leave right VBBB Left ventricular hypertrophy Significant renal hepatic disease Obesity &gt; 30kg/m2 Diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>hypertension</keyword>
	<keyword>pharmacogenomic</keyword>
	<keyword>adducin</keyword>
	<keyword>ouabain</keyword>
	<keyword>rostafuroxin</keyword>
</DOC>